全文获取类型
收费全文 | 348494篇 |
免费 | 23014篇 |
国内免费 | 4235篇 |
专业分类
耳鼻咽喉 | 4821篇 |
儿科学 | 10876篇 |
妇产科学 | 10688篇 |
基础医学 | 49817篇 |
口腔科学 | 8307篇 |
临床医学 | 30603篇 |
内科学 | 61824篇 |
皮肤病学 | 6783篇 |
神经病学 | 23485篇 |
特种医学 | 13752篇 |
外国民族医学 | 67篇 |
外科学 | 52665篇 |
综合类 | 19922篇 |
现状与发展 | 16篇 |
一般理论 | 163篇 |
预防医学 | 24296篇 |
眼科学 | 8092篇 |
药学 | 26676篇 |
55篇 | |
中国医学 | 4271篇 |
肿瘤学 | 18564篇 |
出版年
2022年 | 2935篇 |
2021年 | 4874篇 |
2020年 | 3401篇 |
2019年 | 3704篇 |
2018年 | 5323篇 |
2017年 | 4420篇 |
2016年 | 4655篇 |
2015年 | 6076篇 |
2014年 | 7815篇 |
2013年 | 10469篇 |
2012年 | 13807篇 |
2011年 | 14640篇 |
2010年 | 9959篇 |
2009年 | 8758篇 |
2008年 | 12253篇 |
2007年 | 12968篇 |
2006年 | 12430篇 |
2005年 | 11668篇 |
2004年 | 10427篇 |
2003年 | 9615篇 |
2002年 | 8874篇 |
2001年 | 14199篇 |
2000年 | 14409篇 |
1999年 | 12025篇 |
1998年 | 3401篇 |
1997年 | 3136篇 |
1996年 | 2885篇 |
1995年 | 2798篇 |
1992年 | 8454篇 |
1991年 | 8587篇 |
1990年 | 8370篇 |
1989年 | 8145篇 |
1988年 | 7398篇 |
1987年 | 7148篇 |
1986年 | 6778篇 |
1985年 | 6559篇 |
1984年 | 4793篇 |
1983年 | 4130篇 |
1979年 | 4442篇 |
1978年 | 3237篇 |
1977年 | 2733篇 |
1976年 | 2504篇 |
1975年 | 2835篇 |
1974年 | 3361篇 |
1973年 | 3364篇 |
1972年 | 3124篇 |
1971年 | 2951篇 |
1970年 | 2839篇 |
1969年 | 2584篇 |
1968年 | 2539篇 |
排序方式: 共有10000条查询结果,搜索用时 421 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
3.
Guoliang Zhang & Tao Xiong 《Communications In Computational Physics》2022,32(1):126-155
We propose a high order finite difference linear scheme combined with a
high order bound preserving maximum-principle-preserving (MPP) flux limiter to
solve the incompressible flow system. For such problem with highly oscillatory structure but not strong shocks, our approach seems to be less dissipative and much less
costly than a WENO type scheme, and has high resolution due to a Hermite reconstruction. Spurious numerical oscillations can be controlled by the weak MPP flux
limiter. Numerical tests are performed for the Vlasov-Poisson system, the 2D guiding-center model and the incompressible Euler system. The comparison between the linear
and WENO type schemes, with and without the MPP flux limiter, will demonstrate the
good performance of our proposed approach. 相似文献
4.
目的 探讨Hsa-miR-4282在肝癌细胞系SMMC-7721中的表达及其对细胞生长的影响。方法 采用实时荧光定量PCR法检测Hsa-miR-4282在人正常肝上皮细胞系HL-7702和人肝癌细胞系MHCC97-H、SMMC-7721,以及 20例肝癌组织及其相应癌旁组织中的表达。采用瞬时转染法将Hsa-miR-4282 mimics(上调组)和Hsa-miR-4282 inhibitor(下调组)分别转染肝癌SMMC-7721细胞,上调组和下调组分别设置相应阴性对照组。转染后采用MTT法检测细胞增殖能力,平板克隆形成实验检测细胞克隆形成能力,流式细胞仪检测细胞凋亡能力。结果 Hsa-miR-4282在肝癌组织、肝癌细胞MHCC97-H及肝癌细胞SMMC-7721中的表达均低于癌旁组织及正常肝细胞HL-7702(P<0.05)。MTT实验结果显示,Hsa-miR-4282上调后肝癌SMMC-7721细胞的OD值低于其阴性对照组,而下调后OD值高于其阴性对照组 (P<0.05)。平板克隆形成实验显示,下调组的细胞克隆数高于其阴性对照组[(240±7) 个 vs (191±10) 个,P=0.005)],而上调组细胞克隆数低于基阴性对照组[(146±10) 个 vs (193±12) 个,P=0.013)]。流式细胞仪检测结果显示,Hsa-miR-4282上调组细胞凋亡率较其阴性对照组升高[(23.89±1.89)% vs(16.6±1.14)%,P=0.009)],下调组细胞凋亡率较期阴性对照组降低[(14.98±0.46)% vs (17.79±0.73)%,P=0.010]。结论 Hsa-miR-4282上调可抑制肝癌SMMC-7721细胞增殖,促进细胞凋亡,可能与肝癌的发病机制有关。 相似文献
5.
Breanne E. Kunstler Jill L. Cook Joanne L. Kemp Paul D. O’Halloran Caroline F. Finch 《Journal of Science and Medicine in Sport》2019,22(1):2-10
Objectives
To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.Design
Cross-sectional survey.Method
An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.Results
Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.Conclusions
Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy. 相似文献6.
7.
8.
9.
10.